Roivant Sciences (ROIV) is close to agreeing on a sale of its experimental drug treating ulcerative colitis and Crohn’s disease to Roche (RHHBY) for over $7B, The Wall Street Journal’s Jonathan D. Rockoff, Laura Cooper, and Ben Dummett report, citing people familiar with discussions. Sale of the drug could be announced in the coming days, and the RVT-3101 drug is in the final Phase 3 stage of testing, the report states.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- Roivant Stock (NASDAQ:ROIV) Soars on $7B Potential Sale of Colitis Drug
- Genentech announces OCARINA II trial meets primary, secondary endpoint
- Halozyme announces Roche OCARINA II trial met primary, secondary endpoint
- Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
- European Commission approves Roche’s fixed-duration Columvi